Today: 20 May 2026
Bank of America stock price dips after soft CPI; investors eye Fed minutes and lawsuit risk
13 February 2026
2 mins read

Bank of America stock price dips after soft CPI; investors eye Fed minutes and lawsuit risk

New York, Feb 13, 2026, 15:13 EST — Regular session

  • Bank of America slipped roughly 0.3% to $52.36 as of the afternoon session.
  • U.S. inflation slowed to 2.4% in January, leaving the door open for a possible rate cut in June.
  • The judge gave the green light for an Epstein-linked lawsuit targeting the bank to move forward. U.S. markets will be closed Monday for Presidents Day.

Bank of America Corp (BAC) slipped 0.3% to $52.36 by mid-afternoon Friday, coming off an earlier dip to $51.46. Shares topped out at $52.82 earlier in the session, with volume hovering near 21.8 million.

The stock edged lower, with traders parsing signs of cooling U.S. inflation and questioning the effect of softer rates on banks’ profits. January’s consumer price index ticked up 0.2%, rising 2.4% year-over-year. Market bets coalesced around the Fed trimming rates by June, according to Reuters.

For banks, rate moves cut straight into net interest income—the difference between what they make on loans and securities versus the payouts to depositors. Yields falling? That can pinch margins, despite often giving a lift to bond portfolios and lightening the load for borrowers.

Broader indexes posted slight gains. The SPDR S&P 500 ETF added roughly 0.3%.

Financials weren’t moving much—sector ETF held flat. The bank ETF, on the other hand, managed a slight uptick. Bank of America, though, slipped under that broader bank group for the session.

BAC slid 2.47% Thursday, finishing the session at $52.52. Shares moved between $51.79 and $53.94, Yahoo Finance data showed.

Shares of major banks tumbled that session—Wells Fargo shed close to 3%, while U.S. Bancorp lost roughly 2%. The S&P 500 dropped 1.57% amid a sweeping downturn, according to MarketWatch data.

Bonds surged with investors rushing out of equities, dragging long-end yields down. The 10-year yield dropped 7.8 basis points—each basis point is one-hundredth of a percent—hitting levels not seen since early December, according to MarketWatch.

Strategists couldn’t agree on the impact of Friday’s CPI for the Fed outlook. Phil Orlando over at Federated Hermes described the numbers as “better than expected.” But Josh Jamner from ClearBridge Investments flagged that core services inflation without shelter — the so-called “supercore” — stayed stubbornly hot. Reuters

Still, some sections of the report showed stubborn spots—that’s the kind of thing that can jolt bank stocks. Core inflation, minus food and energy, stayed put at 2.5% year over year, according to the Financial Times. Any uptick in yields threatens to slam the brakes on the rate-cut trade.

Bank of America is staring down a fresh legal headache after a U.S. judge decided Thursday that a proposed class action tied to Jeffrey Epstein’s sex trafficking can move ahead. The trial lands on May 11. The bank maintains it did not act intentionally.

No trading in the U.S. this Monday—markets are shut for Presidents Day. Focus shifts quickly to the Fed’s Jan. 27-28 meeting minutes, set for release Feb. 18. The BEA follows up with its personal income and outlays data, out Feb. 20, which features those PCE price numbers the Fed keeps an eye on.

The next read on the producer price index lands Feb. 27 — a key update for inflation watchers. For BAC, it’s the push and pull between softer headline numbers and persistent strength in services that keeps attention glued to the yield curve, especially as next week approaches.

Stock Market Today

  • Sea Limited (NYSE:SE) Valuation Under Scrutiny After 46% One-Year Share Decline
    May 20, 2026, 10:05 AM EDT. Sea Limited (NYSE:SE), active across e-commerce, digital financial services, and digital entertainment in Southeast Asia and Latin America, has seen its stock fall by 46.26% over the past year. Despite recent share price weakness, some analysts argue the stock trades 36.6% below a $137.64 fair value estimate, buoyed by strong revenue growth from Shopee, Monee, and Garena platforms. Key drivers include accelerating mobile internet penetration, youth digital literacy, and shifts toward cashless payments supporting loan book expansion and improved monetization. Market watchers debate whether this dip offers a buying opportunity or reflects tempered growth prospects, especially as Shopee faces competitive pressures. Investors should weigh Sea's potential for earnings growth against market realities and execution risks.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 12.02.2026

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus
Next Story

Eli Lilly stock: LLY closes at $1,040 as $1.5 billion pill stockpile comes into focus

Go toTop